Published in Oncotarget on June 14, 2016
The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol (2000) 19.46
Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 17.38
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science (2002) 14.20
Multiple myeloma. N Engl J Med (2011) 10.38
Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol (2003) 9.07
MYC oncogenes and human neoplastic disease. Oncogene (1999) 7.28
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
IRF4 addiction in multiple myeloma. Nature (2008) 6.27
Multiple myeloma. Blood (2008) 5.88
Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer (2007) 5.71
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
The genetic architecture of multiple myeloma. Nat Rev Cancer (2012) 3.71
Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene (2008) 3.63
The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol (2007) 3.63
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell (2008) 2.84
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A (2000) 2.81
Addiction to c-MYC in multiple myeloma. Blood (2012) 2.35
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood (2000) 2.08
The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem (2006) 1.96
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood (2001) 1.84
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood (2010) 1.82
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia (2014) 1.56
Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood (1986) 1.51
Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget (2010) 1.40
Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle (2007) 1.26
Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther (2002) 1.24
Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res (2007) 1.22
miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett (2011) 1.21
You Don't Muck with MYC. Genes Cancer (2010) 1.20
TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res (2012) 1.17
Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci U S A (2011) 1.16
Apoptosis and autophagy: decoding calcium signals that mediate life or death. Cold Spring Harb Perspect Biol (2010) 1.13
Initiation of fracture repair by bone morphogenetic proteins. Clin Orthop Relat Res (1998) 1.11
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget (2013) 1.10
Programmed cell death of the normal human neutrophil: an in vitro model of senescence. Microsc Res Tech (1994) 1.08
Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clin Cancer Res (2009) 1.03
Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYC. Leukemia (2011) 0.99
Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother (2007) 0.97
Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res (2012) 0.95
Sendai virus-induced cell fusion. Methods Enzymol (1993) 0.90
Smad9 is a new type of transcriptional regulator in bone morphogenetic protein signaling. Sci Rep (2014) 0.90
MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia (2014) 0.87
Accumulation of cytosolic calcium induces necroptotic cell death in human neuroblastoma. Cancer Res (2013) 0.86
Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus. Leukemia (2008) 0.86
Dentin phosphophoryn activates Smad protein signaling through Ca2+-calmodulin-dependent protein kinase II in undifferentiated mesenchymal cells. J Biol Chem (2013) 0.85
c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB. Int J Immunopathol Pharmacol (2006) 0.84
Multiple calcium-mediated mechanisms regulate c-myc expression in HL-60 cells. J Immunol (1990) 0.83
13-Cis retinoic acid can enhance the antitumor activity of non-replicating Sendai virus particle against neuroblastoma. Cancer Sci (2012) 0.82
Systemic administration of platelets incorporating inactivated Sendai virus eradicates melanoma in mice. Mol Ther (2014) 0.82
Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF-κB-dependent transcriptional control of α2,3-sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells. Int J Cancer (2011) 0.82
Regulation of p27Kip1 accumulation in murine B-lymphoma cells: role of c-Myc and calcium. Cell Growth Differ (1999) 0.81
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int (2015) 0.81
Induction of apoptosis in hormone-resistant human prostate cancer PC3 cells by inactivated Sendai virus. Biomed Environ Sci (2014) 0.81
Development of a transferrin receptor-targeting HVJ-E vector. Biochem Biophys Res Commun (2007) 0.79
Oncolytic virotherapy for multiple myeloma: past, present, and future. Bone Marrow Res (2011) 0.79
Functional modification of Sendai virus by siRNA. J Biotechnol (2008) 0.79
Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application. Cancer Gene Ther (2013) 0.79
Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma. J Neurooncol (2010) 0.77
Transcriptional down-regulation of c-myc expression by protein synthesis-dependent and -independent pathways in a human T lymphoblastic tumor cell line. Cell Growth Differ (1990) 0.76
Platelet-cytokine Complex Suppresses Tumour Growth by Exploiting Intratumoural Thrombin-dependent Platelet Aggregation. Sci Rep (2016) 0.77
Oncolytic Sendai virus-based virotherapy for cancer: recent advances. Oncolytic Virother (2015) 0.76
An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis. Mol Ther (2015) 0.75
Salmonella mediated the hemagglutinating virus of Japan-envelope transfer suppresses tumor growth. Oncotarget (2017) 0.75
Inactivated Sendai virus particle upregulates cancer cell expression of intercellular adhesion molecule-1 and enhances natural killer cell sensitivity on cancer cells. Cancer Sci (2017) 0.75